Vertex’s copay assistance changes add an undue burden for people living with an already expensive, challenging lifelong disease.
Bill will jump-start rebuilding of the antibiotics pipeline that is vital to stave off a looming pandemic.
| 3 min read
Results show that people on Trikafta® enrolled in the six-week study were able to safely stop taking one of the two common CF medications without negatively affecting their health.
| 4 min read
The Cystic Fibrosis Foundation is providing up to $5 million to develop a method to deliver a healthy copy of the CFTR gene into the lung cells of people with CF that is unlikely to trigger an immune system response.
| 4 min read
Addressing variability in newborn screening can prevent missed diagnoses and delays in early care intervention.
| 3 min read
Orkambi® is now approved for use in children with cystic fibrosis ages 1-2 years who have two F508del mutations. This is the only modulator available to very young children with these mutations.
| 3 min read
CEO pledge is part of the Foundation’s ongoing commitment to strengthen the organization and better serve all people with CF
| 3 min read
The law signals major improvements in health care affordability for people with CF.
| 3 min read
The cystic fibrosis care model is evolving to support people living longer with CF and their increasingly diverse health needs. Catalyzed by the approval of Trikafta® and the COVID-19 pandemic, this adaptive and personalized care model encompasses novel ways to connect clinicians and patients.
| 4 min read
Today, there are close to 40,000 people in the United States with CF due in large part to more people living longer into adulthood, signaling a shift in what it means to live with CF in the modern era.
| 4 min read